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Uniparental disomy (UPD) was first described 
in 1980 by Engel and was defined as the occurrence of 
inheriting a pair of homologous chromosomes from 
the same parental origin. Such event, also known as 
constitutional UPD, is caused by segregation errors mostly 
in meiosis and leads to the development of several genetic 
disorders through the gain or loss of imprinted regions, 
or the presence of two identical copies of an abnormal 
gene [1]. The great advance in molecular genetics in the 
last two decades, especially with the development of 
single nucleotide polymorphism (SNP) arrays and next-
generation sequencing, has provided the opportunity to 
systematically identify regions of somatic UPD in cancer, 
commonly known as somatically-acquired UPD (aUPD) 
or copy-neutral loss of heterozygosity (cnLOH) [2, 3].
The detection of allele-specific copy number 
aberrations in tumor cells relies strongly on bioinformatic 
tools that were initially developed for SNP array 
technologies. These methods are strongly dependent on 
each technology-associated signal and noise characteristics, 
tumor ploidy, the cellularity of the samples, variant 
allele bias in heterozygous loci, and the tumor type [4]. 
Moreover, allele-specific copy number analysis requires 
heterozygous SNP markers, which represent on average 
less than 1/3 of the covered positions. Altogether, it is 
common that these models fail to analyze many samples 
or return low confidence predictions. More recently, some 
tools have been proposed for next-generation sequencing 
data. While whole-exome sequencing lacks an even 
coverage of the genome and heterozygous positions, 
leading to a potential lower accuracy, whole-genome 
sequencing data promise highly precise estimates of allele-
specific copy number profiles and a better integration with 
mutational status and epigenetic marks.
Recent reports have shown that aUPD events are 
non-randomly distributed across cancer types, pointing 
out common genomic profiles of aUPD in a tumor-type 
specific manner, which typically coincide with regions of 
genomic losses, both in solid tumors and hematological 
malignancies [5, 6]. In addition, the identification of 
cancer-specific minimal regions of aUPD has led to the 
discovery of inactivating mutations in cancer-related 
genes, which might increase the functional relevance of 
such events in the development of cancer. In fact, several 
studies have provided evidence that aUPD could act as 
the “second hit” in the Knudson hypothesis and inactivate 
tumor suppressor genes. Examples of this phenomenon 
are the inactivation of well-known tumor suppressor genes 
such as APC in colorectal cancer, RB1 in retinoblastoma, 
ARID1A in colorectal and stomach carcinoma, and 
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Figure 1: Circos plots depicting genomic profiles of aUPDs (green), copy number losses (blue) and gains (red) in (A) esophageal 
squamous cell carcinomas (ESCC) and (B) colon adenocarcinomas (COAD). Data was obtained from The Cancer Genome Atlas (TCGA) 
through the NCI Genomics Data Commons (GDC) portal. In the outer ring, the most frequently mutated genes involved in aUPD events 
are indicated for each tumor type. (Adapted from Torabi et al., 2019).
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inactivation of TP53 in several cancer types, including 
glioblastoma, diffuse large B cell lymphoma, and 
colorectal carcinoma, among others [7]. Moreover, some 
studies have identified aUPD in colorectal pre-malignant 
adenomas, mostly affecting APC and SMAD4, two tumor 
suppressor genes known to be involved in early colorectal 
carcinogenesis [8]. Likewise, aUPD also occurs in 
genomic regions including proto-oncogenes such as KRAS 
at 12p, indicating that aUPD also plays a crucial role in the 
activation of oncogenes (Figure 1).
The mechanisms by which aUPD is generated 
remain elusive. aUPD events are either caused by 
chromosome segregation errors in mitosis, leading to 
whole-chromosome aUPD, or by mitotic recombination, 
which acts as a repairing double strand break mechanism 
and might lead to segmental aUPD. In fact, segmental 
aUPD is commonly identified in tumors with impaired 
chromosome repair mechanisms, such as MUTYH-
associated polyposis colon carcinomas [9]. It might 
be plausible to rationalize that mitotic recombination-
associated segmental aUPD might imply two features: 
(i) genomic sites of high sequence homology, which 
coincide with sites of meiotic recombination as seen for 
chromosome 5q breakpoints [10], and (ii) a physical 
proximity of homologous chromosomes that would 
increase the chances of mitotic recombination events, 
especially in aneuploid tumors where the higher-order 
genome organization might be altered.
Several questions remain to be answered to further 
understand the role of aUPD in cancer. The higher 
prevalence of aUPD in certain chromosomal regions 
compared with the frequency of genomic losses (e.g., 
chromosome 5q in colorectal cancer), suggests that tumor 
cells need to preserve such chromosomal regions in two 
or more copies in order to maintain cellular fitness, most 
likely due to the presence of haploinsufficient genes or 
genomic regions under negative selection in a tissue-
specific manner. At the functional level, the transcriptional 
consequences of aUPD, as well as the gene dysregulation 
due to the disruption of imprinted gene clusters during 
the carcinogenesis, prevail largely unknown. Lastly, the 
association between aUPD and disease outcome in large 
cohorts is rather limited. Therefore, additional studies are 
required to elucidate the prognostic potential of recurrent 
aUPD events in cancer.
In summary, although we cannot exclude that a 
second sequence mutation, epigenetic modifications 
or DNA conformational changes might lead to loss-of-
function of tumor suppressor genes or activation of proto-
oncogenes, a substantial amount of literature suggests 
that aUPD represents an unquestionable event to achieve 
a “second hit” alteration during tumorigenesis and its 
identification might be a useful resource in early detection 
and targeted therapy.
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